Company / PP&E (Net)
Larimar Therapeutics, Inc. PP&E (Net) History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$821.0K
FY2019
5-year range
$375.0K / $902.0K
FY2015-FY2019
Trend
+118.9%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) returned to growth in FY2019 after 3 years of decline, reaching $821,000.
Based on SEC 10-K filings.
$821,000 in FY2019 with a 5-year CAGR of +59.7%.
Improved from $528,000 to $821,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +7.5%
- 5-Year CAGR
- +59.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +59.7%, indicating consistent growth.
- In FY2019, pp&e (net) increased 118.9% year-over-year.
- Peak pp&e (net) was recorded in FY2015.
- Lowest pp&e (net) in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2019 | $821.0K | +118.9% |
| FY2018 | $375.0K | -29.0% |
| FY2017 | $528.0K | -20.1% |
| FY2016 | $661.0K | -26.7% |
| FY2015 | $902.0K | +1041.8% |
| FY2014 | $79.0K | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026